How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years

Autor: Frédéric Blanc, Adrien Julian, Julie Bellet, Julien Dumurgier, Claire Boutoleau-Bretonnière, Renaud David, David Wallon, Jacques Hugon, P. Robert, Emmanuelle Liegey, Aurélie Mouton, Florence Pasquier, Claire Paquet, Samir Bekadar, Marc Paccalin, Stéphane Epelbaum, Didier Hannequin, Thérèse Rivasseau Jonveaux, Annick Besozzi, Bruno Dubois, Caroline Hommet, Roxane Fabre, Laetitia Berly, Olivier Madec, Walter Deberdt, Tiphaine Charriau, Olivier Rouaud, Stéphane Pouponneau

Publikováno v: BMJ Open, Vol 9, Iss 6 (2019)
BMJ Open
BMJ Open, BMJ Publishing Group, 2019, 9 (6), pp.e029663. ⟨10.1136/bmjopen-2019-029663⟩
BMJ Open, 2019, 9 (6), pp.e029663. ⟨10.1136/bmjopen-2019-029663⟩

ObjectiveWe aimed to study the epidemiology of the prodromal and mild stages of Alzheimer’s disease (AD) patients who are eligible for clinical trials with disease-modifying therapies.SettingsWe analysed two large complementary databases to study t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa8a88ce003dffdd833422c7dad923cd
https://bmjopen.bmj.com/content/9/6/e029663.full